Table 1 Baseline characteristics of patients according to pretreatment T790M status
Characteristics | Number of patients, n (%) | P | |||||
|---|---|---|---|---|---|---|---|
All (n = 373) | Pretreatment T790M | ||||||
High (n = 151, 40.5%) | Low (n = 222, 59.5%) | ||||||
Age | 0.67 | ||||||
 Median (range) | 69 | (30–92) | 69 | (37–88) | 69 | (30–92) | |
  < 70 | 191 | (51.2) | 75 | (49.7) | 116 | (52.3) | |
  ≥ 70 | 182 | (48.8) | 76 | (50.3) | 106 | (47.7) | |
Gender | 0.47 | ||||||
 Male | 97 | (26.0) | 36 | (23.8) | 61 | (27.5) | |
 Female | 276 | (74.0) | 115 | (76.2) | 161 | (72.5) | |
Smoking | 0.0050 | ||||||
 Never smoker | 280 | (75.1) | 125 | (82.8) | 155 | (69.8) | |
 Smoker | 93 | (24.9) | 26 | (17.2) | 67 | (30.2) | |
Histology | 0.24 | ||||||
 Adenocarcinoma | 361 | (96.8) | 144 | (95.4) | 217 | (97.7) | |
 Other | 12 | (3.2) | 7 | (4.6) | 5 | (2.3) | |
Pathological Stage (7th) | 0.42 | ||||||
 IA | 219 | (58.7) | 84 | (55.6) | 135 | (60.8) | |
 IB-II | 114 | (30.6) | 52 | (34.4) | 62 | (27.9) | |
 III-IV | 40 | (10.7) | 15 | (9.9) | 25 | (11.3) | |
EGFR Mt Status | 0.92 | ||||||
 Exon21 L858R | 199 | (53.4) | 82 | (54.3) | 117 | (52.7) | |
 Exon19 deletion | 155 | (41.6) | 62 | (41.1) | 93 | (41.9) | |
 Uncommon | 19 | (5.1) | 7 | (4.6) | 12 | (5.4) | |
Adjuvant Chemotherapy | (69.8) | 0.37 | |||||
 No | 253 | (67.8) | 98 | (64.9) | 155 | (30.2) | |
 Yes | 120 | (32.2) | 53 | (35.1) | 67 | ||
 UFT | 73 |  | 32 |  | 41 | ||
 Platinum doublet | 34 |  | 18 |  | 16 | ||
 EGFR-TKI | 7 |  | 1 |  | 6 | ||
 Other | 6 |  | 2 |  | 4 | ||
TP53 Mt Status | (78.4) | 0.077 | |||||
 Wild-type | 304 | (81.5) | 130 | (86.1) | 174 | ||
 Mutant | 69 | (18.5) | 21 | (13.9) | 48 | (21.6) | |
Co-existing except TP53 Mt | (89.2) | 0.52 | |||||
 No | 329 | (88.2) | 131 | (86.8) | 198 | (10.8) | |
 Yes | 44 | (11.8) | 20 | (13.2) | 24 | ||